Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma.

Patoulias, Dimitrios; Dimosiari, Athina; Michailidis, Theodoros

Patoulias, Dimitrios; Dimosiari, Athina; Michailidis, Theodoros.

Patoulias D; Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital "Hippokration", Greece. Electronic address: dipatoulias@gmail.com.
Dimosiari A; Department of Emergency Medicine, General Hospital "Hippokration", Thessaloniki, Greece.
Michailidis T; Second Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital "Hippokration", Greece.

Eur J Intern Med ; 90: 107-108, 2021 08.

Article in English | MEDLINE | ID: covidwho-1252809

Subject(s)

COVID-19 Drug Treatment; Interleukin 1 Receptor Antagonist Protein; Antibodies, Monoclonal, Humanized; Humans; SARS-CoV-2

Keywords

Anakinra; COVID-19; Mortality; Tocilizumab

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Interleukin 1 Receptor Antagonist Protein / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Eur J Intern Med Journal subject: Internal Medicine Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google